Alkermes (NASDAQ:ALKS) EVP David Joseph Gaffin Sells 2,034 Shares of Stock

Posted by George Bondi on Aug 4th, 2026

Alkermes plc (NASDAQ:ALKS – Get Free Report) EVP David Joseph Gaffin sold 2,034 shares of the company’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $48.58, for a total transaction of $98,811.72. Following the completion of the sale, the executive vice president owned 225,456 shares in the company, valued at $10,952,652.48. This represents a 0.89% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

David Joseph Gaffin also recently made the following trade(s):

On Monday, July 6th, David Joseph Gaffin sold 2,034 shares of Alkermes stock. The shares were sold at an average price of $54.03, for a total value of $109,897.02.
On Thursday, June 4th, David Joseph Gaffin sold 2,034 shares of Alkermes stock. The shares were sold at an average price of $43.05, for a total value of $87,563.70.

Alkermes Stock Performance

Shares of ALKS opened at $49.53 on Tuesday. The firm has a market capitalization of $8.31 billion, a P/E ratio of 130.35 and a beta of 0.34. Alkermes plc has a 52 week low of $25.17 and a 52 week high of $55.67. The stock has a 50 day moving average price of $48.49 and a two-hundred day moving average price of $38.38. The company has a debt-to-equity ratio of 0.82, a quick ratio of 1.85 and a current ratio of 2.30.

Institutional Investors Weigh In On Alkermes

Large investors have recently made changes to their positions in the business. Norges Bank bought a new position in shares of Alkermes during the 4th quarter valued at approximately $54,442,000. Baker BROS. Advisors LP raised its holdings in shares of Alkermes by 23.7% in the 4th quarter. Baker BROS. Advisors LP now owns 10,012,267 shares of the company’s stock worth $280,143,000 after purchasing an additional 1,920,916 shares during the period. UBS Group AG lifted its stake in Alkermes by 237.4% in the fourth quarter. UBS Group AG now owns 2,544,895 shares of the company’s stock valued at $71,206,000 after purchasing an additional 1,790,729 shares during the last quarter. First Trust Advisors LP lifted its stake in Alkermes by 104.2% in the first quarter. First Trust Advisors LP now owns 2,968,785 shares of the company’s stock valued at $104,976,000 after purchasing an additional 1,514,783 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in Alkermes by 32.0% during the fourth quarter. JPMorgan Chase & Co. now owns 5,184,547 shares of the company’s stock valued at $145,064,000 after purchasing an additional 1,256,377 shares during the period. 95.21% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently commented on ALKS. Mizuho increased their price target on Alkermes from $53.00 to $65.00 and gave the company an “outperform” rating in a research report on Thursday, July 2nd. Royal Bank Of Canada lifted their price objective on shares of Alkermes from $45.00 to $56.00 and gave the stock an “outperform” rating in a report on Tuesday, June 9th. Zacks Research upgraded shares of Alkermes from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. TD Cowen increased their target price on shares of Alkermes from $42.00 to $50.00 and gave the company a “buy” rating in a report on Monday, June 22nd. Finally, UBS Group raised their price target on shares of Alkermes from $42.00 to $48.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $54.56.

Get Our Latest Stock Report on Alkermes

Key Alkermes News

Here are the key news stories impacting Alkermes this week:

Positive Sentiment: Analysts have assigned Alkermes a consensus rating of “Moderate Buy,” indicating that Wall Street’s overall stance remains favorable toward the company and its outlook. Alkermes Receives Consensus Recommendation of Moderate Buy
Neutral Sentiment: HC Wainwright published an estimate for Alkermes’ third-quarter earnings. The report could influence trading as investors assess whether upcoming results can support the company’s premium valuation, although the specific estimate was not provided. HC Wainwright Estimates Alkermes’ Q3 Earnings
Negative Sentiment: Director Nancy Lynn Md Snyderman sold 44,472 ALKS shares for approximately $2.24 million, reducing her direct ownership by about 74%. The sizable sale may raise concern about insider confidence, although the filing does not establish that the transaction reflects a negative view of the business. SEC insider transaction filing
Negative Sentiment: EVP Craig C. Hopkinson sold 9,000 shares valued at roughly $437,000, cutting his direct holdings by 11.48%. The sale was made under a pre-arranged Rule 10b5-1 trading plan, which reduces its significance as a discretionary bearish signal. SEC insider transaction filing
Negative Sentiment: EVP David Joseph Gaffin sold 2,034 shares for approximately $99,000, reducing ownership by 0.89%. This transaction also occurred under a pre-arranged Rule 10b5-1 plan and is relatively small compared with his remaining stake. SEC insider transaction filing

About Alkermes

(Get Free Report)

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.